ALTIMMUNE (NASDAQ: ALT) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by October 6, 2025

PHILADELPHIA, Sept. 25, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) after a class action lawsuit was filed against Altimmune.

Read more at prnewswire.com